QIAGEN (QGEN) Company Report

Analyst Coverage

Research analysts who have asked questions during QIAGEN earnings calls.

Casey Woodring

JPMorgan Chase & Co.

4 questions for QGEN

Also covers: A, BLLN, CRL +10 more

Michael Ryskin

Bank of America Merrill Lynch

4 questions for QGEN

Also covers: A, ALGN, AVTR +28 more

Daniel Brennan

TD Cowen

3 questions for QGEN

Also covers: A, ADPT, AVTR +24 more

Matthew Sykes

Goldman Sachs Group Inc.

3 questions for QGEN

Also covers: A, ADPT, AVTR +21 more

Patrick Donnelly

Citi

3 questions for QGEN

Also covers: A, AVTR, BIO +21 more

Tycho Peterson

Jefferies

3 questions for QGEN

Also covers: A, AVTR, BIO +22 more

Aisyah Noor

Morgan Stanley

2 questions for QGEN

Douglas Schenkel

Wolfe Research, LLC

2 questions for QGEN

Also covers: A, AVTR, BRKR +21 more

Doug Schenkel

Wolfe Research LLC

2 questions for QGEN

Also covers: A, AVTR, BRKR +15 more

Hugo Solvet

BNP Paribas

2 questions for QGEN

Also covers: FMS, GNNDY, PHG

Jack Meehan

Nephron Research LLC

2 questions for QGEN

Also covers: A, AVTR, BIO +17 more

Jan Koch

Deutsche Bank AG

2 questions for QGEN

Andrew Brackmann

William Blair & Company, L.L.C.

1 question for QGEN

Also covers: ADPT, AWH, BDSX +11 more

Catherine Schulte

Baird

1 question for QGEN

Also covers: A, CSTL, EXAS +7 more

Daniel Arias

Stifel, Nicolaus & Company, Incorporated

1 question for QGEN

Also covers: A, AVTR, CDXS +15 more

Daniel Leonard

Stifel Financial Corp.

1 question for QGEN

Also covers: A, AVTR, BIO +15 more

Dan Leonard

UBS Group AG

1 question for QGEN

Also covers: A, AVTR, BIO +9 more

Harry Gillis

Berenberg

1 question for QGEN

Also covers: BNTX

Odysseas Manesiotis

Berenberg

1 question for QGEN

Salem Salem

Barclays

1 question for QGEN

Also covers: GH, IQV, PACB +3 more

Latest news

Recent press releases and 8-K filings for QGEN.

QIAGEN outlines 2026 priorities and 2028 growth targets

QGEN

Guidance Update

Product Launch

M&A

QIAGEN has set priorities for 2026, including new product launches and regulatory milestones, to support its goal of achieving at least $2 billion in total annual sales by 2028 across its five growth drivers.
The acquisition of Parse Biosciences in December 2025 is projected to contribute approximately $40 million in revenue in 2026, expanding QIAGEN's sample technologies into single-cell analysis.
For 2026, QIAGEN plans to introduce three new sample preparation systems (QIAsymphony Connect, QIAsprint Connect, and QIAmini) and expand the QIAstat-Dx menu with new blood culture identification panels submitted for regulatory approval.
By the end of 2025, the company had installed over 5,200 QIAstat-Dx devices and over 3,200 QIAcuity digital PCR systems worldwide, strengthening its installed base for recurring consumables and software revenue.
QIAGEN Digital Insights (QDI) aims to introduce at least 14 AI-enabled software solutions by 2028, with new AI functionalities for pharmaceutical R&D and clinical reporting planned for 2026.

3 days ago

Press Release

QIAGEN Provides 2025 Performance Update and 2026 Outlook at J.P. Morgan Healthcare Conference

QGEN

Guidance Update

Product Launch

M&A

QIAGEN expects 5%-6% core growth (CER) and $2.38 EPS for full year 2025, and anticipates 5%-7% revenue growth in 2026, including $40 million from the Parse Biosciences acquisition.
The company is on track to achieve its 2028 targets, including 7% CAGR sales growth, 31% EBIT margin (with potential to exceed), and at least $1 billion in capital returns to shareholders.
QIAGEN is launching three new sample technology instruments in 2026, and continues to see double-digit growth in QuantiFERON and QIAcuity (digital PCR), with QIAstat-Dx maintaining a solid number two position in syndromic testing.
Recent strategic acquisitions include Parse Biosciences (December) and Genoox (summer 2025), complementing its focus on bolt-on M&A, alongside an active share repurchase program and a new recurring dividend policy.

3 days ago

Transcript

QIAGEN Provides 2025 Performance Update and 2026 Outlook at J.P. Morgan Healthcare Conference

QGEN

Guidance Update

Product Launch

M&A

QIAGEN's CEO expressed confidence in the company's Q4 and full year 2025 performance, aligning with guidance of 5% to 6% core growth (CER) and $2.38 EPS.
For 2026, QIAGEN anticipates 5%-7% revenue growth, which includes approximately $40 million from the Parse Biosciences acquisition. The company expects a more favorable market environment, with capital expenditures improving in the second half of the year.
The company is launching three new instruments in sample technology in 2026 (QIAsymphony Connect, QIAsprint Connect, QIAmini). Key growth pillars like QuantiFERON, QIAcuity, and QIAstat-Dx are projected to maintain double-digit growth.
QIAGEN recently completed the acquisitions of Parse Biosciences and Genoox. The company has exceeded its commitment to return at least $1 billion to shareholders by 2028, including a recent $500 million share buyback and the introduction of a recurring dividend policy.

3 days ago

Transcript

QIAGEN Updates on 2025 Performance, 2026 Outlook, and Strategic Initiatives

QGEN

Guidance Update

M&A

Share Buyback

QIAGEN expects to achieve its 2025 guidance of 5%-6% core growth (CER) and $2.38 EPS, and anticipates 5%-7% revenue growth in 2026, with Parse Biosciences contributing $40 million. The company also reiterated its 2028 targets of 7% CAGR, $2.6 billion in total revenues, and an EBIT margin of at least 31%.
The company continues its capital allocation strategy, recently completing a $500 million share buyback and returning another $500 million to shareholders in January, alongside a recurring dividend policy introduced in 2025.
Strategic acquisitions in 2025 included Parse Biosciences and Genoox, aimed at enhancing sample technology and bioinformatics portfolios. Additionally, QIAGEN plans to launch three new sample technology instruments in 2026: QIAsymphony Connect, QIAsprint Connect, and QIAmini.

3 days ago

Transcript

QIAGEN Announces Details of Synthetic Share Repurchase Completion

QGEN

Share Buyback

Dividends

Guidance Update

QIAGEN announced details for the completion of its synthetic share repurchase of approximately $500 million, which is expected to conclude on or around January 7, 2026.
This program combines an immediate capital return with a reverse stock split, aiming to increase earnings per share (EPS) and reduce outstanding shares by approximately 5%.
The share consolidation will convert 20 existing QIAGEN shares into 19 new QIAGEN shares, leading to a reduction of about 10.9 million shares from the 217.7 million outstanding as of December 18, 2025, and a capital repayment of $2.29 per pre-split share.
With this completion, QIAGEN will fulfill its commitment to return $1 billion to shareholders by the end of 2028 significantly earlier than planned.

Dec 18, 2025, 4:28 PM

Press Release

QIAGEN Details Completion of $500 Million Synthetic Share Repurchase

QGEN

Share Buyback

QIAGEN announced details for the completion of a synthetic share repurchase of up to approximately $500 million, which is scheduled to be completed on January 7, 2026.
This capital return method combines a direct capital repayment to shareholders with a reverse stock split, designed to enhance earnings per share (EPS).
The terms include consolidating every 20 issued QIAGEN shares into 19 shares, leading to an approximate 5% reduction in the number of issued shares and a repayment of $2.29 per pre-consolidation share.
With the completion of this repurchase, QIAGEN will have delivered ahead of schedule on its commitment to return at least $1 billion to shareholders by the end of 2028.

Dec 18, 2025, 4:27 PM

Press Release

Qiagen Reports Strong Organic Growth, Discusses CEO Transition and Future Product Launches

QGEN

Revenue Acceleration/Inflection

CEO Change

M&A

Qiagen reported strong organic growth of 7% in Q1 and 6% in Q2 and Q3, driven by its strategy and the resilience of its 85% consumables-based business.
The company announced a CEO transition and issued a cautious Q4 guidance, citing NIH funding constraints and academic shutdowns impacting instrumentation sales.
Key growth drivers include QuantiFERON (TB testing) and strong placements of QIAstat-Dx instruments, with an anticipated inflection in the sample technology business in 2026 due to new platform launches.
The recent acquisition of Pars Biosciences is expected to contribute $40 million in revenue next year and, despite creating approximately 200 basis points of margin headwinds in 2026, Qiagen aims for flattish margins and plans to update its 31% midterm margin target for 2028.

Dec 3, 2025, 3:50 PM

Transcript

QGEN Discusses Strong 2025 Performance, CEO Transition, and 2026 Growth Drivers

QGEN

CEO Change

Product Launch

Guidance Update

QGEN's organic growth was strong in the first three quarters of 2025, with 7% in Q1 and 6% in Q2 and Q3, outperforming life science tools peers, largely due to its resilient consumables-based business.
The company is undergoing a CEO transition, with Thierry transitioning out after six years as CEO, and a search for a successor is underway with a typical European timeframe of three to six months.
Qiagen anticipates significant product launches in 2026, including the fifth generation of QuantiFERON (with some products launching in 2026 and 2027) and new sample prep platforms like QIAsprint and QIAmini (both launching mid-2026), which are expected to be important inflection points for the Sample Tech segment.
For 2026, the consensus EPS is around $2.50, and despite anticipated headwinds of approximately 200 basis points from the Pars acquisition, currency, and tariffs, margins are expected to remain flattish due to operational improvements and a favorable product mix.

Dec 3, 2025, 3:50 PM

Transcript

QIAGEN Discusses Q3 Performance, CEO Transition, and 2026 Outlook

QGEN

Product Launch

M&A

CEO Change

QIAGEN reported 7% growth in Q1 and 6% growth in Q2 and Q3, with 85% of its business in resilient consumables.
The company is undergoing a CEO transition, with the search for a successor expected to conclude within 3 to 6 months.
Key product developments include the upcoming fifth generation of QuantiFERON (launching 2026-2027) and new sample prep platforms like QIAsymphony Connect (H1 2026) and QIAsprint (mid-2026), which targets a new high-throughput market.
The Pars acquisition is projected to contribute $40 million in revenue in 2026 and is expected to be margin accretive over time.
Despite an anticipated 200 basis points of margin headwind for 2026, QIAGEN expects margins to remain flattish due to operational efficiencies and a favorable product mix, with a midterm target of 31% by 2028.

Dec 3, 2025, 3:50 PM

Transcript

QIAGEN Reports Strong Q3 2025 Results and Raises Full-Year EPS Outlook

QGEN

Earnings

Guidance Update

New Projects/Investments

QIAGEN reported net sales of $533 million (+5% CER) and adjusted diluted EPS of $0.61 (+7% CER) for Q3 2025, with adjusted EPS exceeding its outlook.
The company reaffirmed its 2025 net sales outlook of +4-5% CER and increased its adjusted diluted EPS outlook to ~$2.38 CER for the full year.
Growth in Q3 2025 was led by QuantiFERON (+11% CER) and QIAstat-Dx (+11% CER). QIAGEN is targeting a ~7% net sales CER CAGR and ≥31% adjusted operating income margin CER by 2028, with over $2 billion in net sales from growth pillars.
QIAGEN is expanding its portfolio with new automation solutions and the acquisition of Parse Biosciences, which is expected to contribute ~$40 million in sales in 2026. The company also plans at least $1 billion in returns to shareholders from 2024-2028 and has a $500 million share repurchase program to be completed by January 2026.